+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • ID: 5441963
  • Report
  • September 2021
  • Region: Global
  • 147 Pages
  • IMARC Group

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
The global orphan drugs market reached a value of US$ 174.7 Billion in 2020. Looking forward, the market is expected to grow at a CAGR of 9.8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Breakup by Drug Type

  • Biological
  • Non-Biological

Breakup by Disease Type

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

Breakup by Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Breakup by Top Selling Drugs

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Others

Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Region

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape


The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • How has the global orphan drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global orphan drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the phase?
  • What is the breakup of the market based on the top selling drugs?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global orphan drugs market and who are the key players?
  • What is the degree of competition in the industry?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Orphan Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Type
6.1 Biological
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Non-Biological
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Disease Type
7.1 Oncology
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Hematology
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Neurology
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cardiovascular
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast

8 Market Breakup by Phase
8.1 Phase I
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Phase II
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Phase III
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Phase IV
8.4.1 Market Trends
8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs
9.1 Revlimid
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Rituxan
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Copaxone
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Opdivo
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Keytruda
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Imbruvica
9.6.1 Market Trends
9.6.2 Market Forecast
9.7 Avonex
9.7.1 Market Trends
9.7.2 Market Forecast
9.8 Sensipar
9.8.1 Market Trends
9.8.2 Market Forecast
9.9 Soliris
9.9.1 Market Trends
9.9.2 Market Forecast
9.10 Others
9.10.1 Market Trends
9.10.2 Market Forecast

10 Market Breakup by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Retail Pharmacies
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Online Stores
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast

11 Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast

12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 AbbVie Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Alexion Pharmaceuticals Inc.
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.3 Amgen Inc.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Biogen Inc.
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 Financials
16.3.4.4 SWOT Analysis
16.3.5 Bristol Myers Squibb Company
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 SWOT Analysis
16.3.7 Jazz Pharmaceuticals PLC
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Johnson & Johnson
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 Merck & Co. Inc.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.9.4 SWOT Analysis
16.3.10 Novartis AG
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Pfizer Inc.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
16.3.12 Sanofi S.A.
16.3.12.1 Company Overview
16.3.12.2 Product Portfolio
16.3.12.3 Financials
16.3.12.4 SWOT Analysis
16.3.13 Takeda Pharmaceutical Company Limited
16.3.13.1 Company Overview
16.3.13.2 Product Portfolio
16.3.13.3 Financials
16.3.13.4 SWOT Analysis
16.3.14 Teva Pharmaceutical Industries Ltd
16.3.14.1 Company Overview
16.3.14.2 Product Portfolio
16.3.14.3 Financials
16.3.14.4 SWOT Analysis

List of Figures
Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2020
Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2020
Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2020
Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2020
Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2020
Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2020
Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2015 & 2020
Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2015 & 2020
Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2015 & 2020
Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2015 & 2020
Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2015 & 2020
Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2015 & 2020
Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2015 & 2020
Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2015 & 2020
Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2015 & 2020
Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2015 & 2020
Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2015 & 2020
Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2015 & 2020
Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2015 & 2020
Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2015 & 2020
Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2015 & 2020
Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2015 & 2020
Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2015 & 2020
Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2015 & 2020
Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2015 & 2020
Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2015 & 2020
Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2015 & 2020
Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2015 & 2020
Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
Figure 110: Global: Orphan Drugs Industry: Porter’s Five Forces Analysis

List of Tables
Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2021-2026
Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2021-2026
Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2021-2026
Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 8: Global: Orphan Drugs Market Structure
Table 9: Global: Orphan Drugs Market: Key Players
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll